🇺🇸 FDA
Patent

US 7884091

Methods for treating delirium using glucocorticoid receptor-specific antagonists

granted A61KA61K31/47A61K31/573

Quick answer

US patent 7884091 (Methods for treating delirium using glucocorticoid receptor-specific antagonists) held by Corcept Therapeutics Incorporated expires Mon Feb 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Feb 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/47, A61K31/573